Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Maintenance & consolidation strategies for ALL and their impact on QoL

Irene Urbino • 12 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab

Irene Urbino, MD, Città della Salute e della Scienza di Torino, Turin, Italy, outlines the various maintenance and consolidation strategies for the treatment of acute lymphoblastic leukemia (ALL), including blinatumomab, and further comments on the impact of maintenance strategies on the patient’s quality of life (QoL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Irene Urbino

2:28
Blinatumomab as consolidation for adult B-ALL
Irene Urbino • 12 Jun 2022
1:36
Chemotherapy and alloHSCT in the treatment of ALL
Irene Urbino • 12 Jun 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals